Benzinga··NaLigand to Acquire XOMA Royalty for $739M, Bolstering Biopharma Portfolio to 200+ Assets
Ligand Pharmaceuticals to acquire XOMA Royalty for $39/share in $739M cash deal, expanding portfolio and raising 2026 EPS guidance.
LGNDXOMAXOMAOXOMAPacquisitionbiopharmaceutical